CS
DBTX

Credit Suisse’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Credit Suisse’s Portfolio DBTX Stock Details DBTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-251,950
Closed -$1.94M – 4716
2021
Q3 		$1.94M Sell
251,950
-1,901
-0.7% -$14.5K ﹤0.01% 2842
2021
Q2 		$2.18M Buy
+253,851
New +$2.24M ﹤0.01% 2796

Other funds holding DBTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Credit Suisse's DBTX Position: Q4 2021 in Review

Credit Suisse sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q4 2021, closing a stake of 251,950 shares — an estimated $1.94M sold.

Credit Suisse first reported a position in DBTX in Q2 2021 and held it in 2 quarters. The position peaked at $2.18M in Q2 2021. 40 funds tracked by Wall St. Rank hold DBTX as of Q4 2021.

  • Credit Suisse reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Credit Suisse sold 251,950 Decibel Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $1.94M.
  • Credit Suisse first reported a position in Decibel Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Credit Suisse's Decibel Therapeutics, Inc. Common Stock position peaked at $2.18M in Q2 2021.
  • 40 funds tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Credit Suisse's 13F filing for Q4 2021, filed 14 Feb 2022.